<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03910842</url>
  </required_header>
  <id_info>
    <org_study_id>T2018-14</org_study_id>
    <nct_id>NCT03910842</nct_id>
  </id_info>
  <brief_title>Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy</brief_title>
  <official_title>Adoptive Immunotherapy for Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Timmune Biotech Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hunan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Timmune Biotech Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, early phase Ⅰ study, to determine the safety and efficacy&#xD;
      of CD19-TriCAR-T and CD19-TriCAR-SILK cell therapy in Children CD19+ Leukemia Non-Hodgkin&#xD;
      lymphoma treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD19-TriCAR contains an anti-CD19 scFv, a PD-L1 blocker, and a cytokine complex, enabling the&#xD;
      CD19-TriCAR-T/SILK to simultaneously targeting the CD19 positive Leukemia or Non-Hodgkin&#xD;
      lymphoma，blocking the inhibitory PD-L1 signal and stimulating innate T/NK cell activation and&#xD;
      expansion, thus make it a tri- functional CAR (Tri-CAR). CD19-TriCAR-T is an autologous&#xD;
      tri-functional CAR-T cell therapy, CD19-TriCAR-SILK is an Allogeneic tri-functional CAR- NK&#xD;
      cell therapy, patients ineligible for leukapheresis or CAR-T therapy will be recommended for&#xD;
      CD19-TriCAR-SILK therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2019</start_date>
  <completion_date type="Anticipated">October 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safty (Incidence of treatment-related adverse events as assessed by CTCAE v4.03)</measure>
    <time_frame>24 monthes</time_frame>
    <description>Incidence of treatment-related adverse events as assessed by CTCAE v4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate[CR] (Complete response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma)</measure>
    <time_frame>24 monthes</time_frame>
    <description>Complete response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Partial response rate [PR] （Partial response rate per the revised International Working Group (IWG) Response Criteria）</measure>
    <time_frame>24 monthes</time_frame>
    <description>Partial response rate per the revised International Working Group (IWG) Response Criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of Response （The time from response to relapse or progression）</measure>
    <time_frame>24 monthes</time_frame>
    <description>The time from response to relapse or progression</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression Free Survival （The time from the first day of treatment to the date on which disease progresses）</measure>
    <time_frame>24 monthes</time_frame>
    <description>The time from the first day of treatment to the date on which disease progresses</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Survival （The number of patient alive, with or without signs of cancer）</measure>
    <time_frame>24 monthes</time_frame>
    <description>The number of patient alive, with or without signs of cancer</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Non-Hodgkin Lymphoma of Intestine</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>CD19-TriCAR-T/NK（SILK）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD19-TriCAR-T/SILK cells will be administered intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19-TriCAR-T/SILK</intervention_name>
    <description>A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.</description>
    <arm_group_label>CD19-TriCAR-T/NK（SILK）</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For children CD19 positive B cell leukemia：&#xD;
&#xD;
          1. All subjects must personally sign and date the Informed Consent before initiating any&#xD;
             study specific procedures or activities;&#xD;
&#xD;
          2. All subjects must be able to comply with all the scheduled procedures in the study;&#xD;
&#xD;
          3. CD19-positive B-cell leukemia with histology or cytology confirmed recurrence after&#xD;
             treatment; or progression during treatment; or after first line treatment getting a&#xD;
             MRD negative, 2 times of MRD show&gt;0.01% but without bone marrow morphology recurrence;&#xD;
&#xD;
          4. At least one measurable lesion;&#xD;
&#xD;
          5. Aged &lt;18 years; or diagnosised at the age of less than 18 and relapsed within three&#xD;
             years， determined by the investigator;&#xD;
&#xD;
          6. Expected survival ≥12 weeks;&#xD;
&#xD;
          7. Eastern cooperative oncology group(ECOG) performance status of≤2;&#xD;
&#xD;
          8. Before CD19-TriCAR-T/SILK cell infusion, systematic usage of immunosuppressive drug or&#xD;
             corticosteroid must have been stopped for more than 4 weeks;&#xD;
&#xD;
          9. All other treatment induced adverse events must have been resolved to ≤grade 1;&#xD;
&#xD;
        For children CD19 positive B cell lymphoma：&#xD;
&#xD;
          1. All subjects must personally sign and date the Informed Consent before initiating any&#xD;
             study specific procedures or activities;&#xD;
&#xD;
          2. All subjects must be able to comply with all the scheduled procedures in the study;&#xD;
&#xD;
          3. CD19-positive B-cell lymphoma with histology or cytology confirmed recurrence after&#xD;
             treatment，defined as one or more of the following: disease progression during standard&#xD;
             therapy；recurrence after termination of treatment；relapse after autologous&#xD;
             hematopoietic stem cell transplantation；not suitable for stem cell transplantation or&#xD;
             abandon stem cell transplantation due to conditional restrictions;&#xD;
&#xD;
          4. At least one measurable lesion;&#xD;
&#xD;
          5. Aged &lt;18 years; or diagnosised at the age of less than 18 and relapsed within three&#xD;
             years， determined by the investigator;&#xD;
&#xD;
          6. Expected survival ≥12 weeks;&#xD;
&#xD;
          7. Eastern cooperative oncology group(ECOG) performance status of≤2;&#xD;
&#xD;
          8. Before CD19-TriCAR-T/SILK cell infusion, systematic usage of immunosuppressive drug or&#xD;
             corticosteroid must have been stopped for more than 4 weeks;&#xD;
&#xD;
          9. All other treatment induced adverse events must have been resolved to ≤grade 1;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or&#xD;
             requiring iv antimicrobials for management. (Simple UTI and uncomplicated bacterial&#xD;
             pharyngitis are permitted if responding to active treatment);&#xD;
&#xD;
          2. Patients with symptomatic central nervous system metastasis, intracranial metastasis,&#xD;
             and cancer cells found in cerebrospinal fluid are not recommended to participate in&#xD;
             this study. Symptom free or post-treatment stable disease or disappearance of lesions&#xD;
             should not be excluded. The specific selection is ultimately determined by the&#xD;
             investigator;&#xD;
&#xD;
          3. Lactating women or women of childbearing age who plan to conceive during the time&#xD;
             period;&#xD;
&#xD;
          4. Active infection with hepatitis B (HBsAG positive) or hepatitis C virus (anti-HCV&#xD;
             positive);&#xD;
&#xD;
          5. Known history of infection with HIV;&#xD;
&#xD;
          6. Subjects need systematic usage of corticosteroid;&#xD;
&#xD;
          7. Subjects need systematic usage of immunosuppressive drug;&#xD;
&#xD;
          8. Planed operation, history of other related disease, or any other related laboratory&#xD;
             tests restrict patients for the study;&#xD;
&#xD;
          9. Other reasons the investigator consider the patient may not be suitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiangling He</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiangling He</last_name>
    <phone>+86 13873102615</phone>
    <email>hexiangl@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keke Chen</last_name>
    <phone>+86 13974931408</phone>
    <email>chenkeke1982@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hunan Provincial People's Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangling He</last_name>
      <phone>+86 13873102615</phone>
      <email>hexiangl@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Keke Chen</last_name>
      <phone>+86 13974931408</phone>
      <email>chenkeke1982@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiangling He</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>children</keyword>
  <keyword>CD19</keyword>
  <keyword>CAR-T</keyword>
  <keyword>TriCAR-T</keyword>
  <keyword>TriCAR-SILK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

